Chapter 14 — The Economics of Healthcare

Why the Market for Medicine Doesn't Work Like the Market for Pizza

When you buy a pizza, the transaction is simple. You know what you want (pizza). You know what it costs ($12). You can compare options (Luigi's vs. Domino's vs. the campus cafeteria). You can walk away if the price is too high. You consume the pizza yourself and bear the full cost. The market works roughly the way Chapter 5 described: supply meets demand at a price both parties accept.

When you visit a hospital, almost none of this is true. You often don't know what you need (the doctor decides). You don't know what it costs (you may not see a bill for weeks or months, and the bill may bear no relationship to what was discussed in advance). You can't easily compare options (try calling three hospitals while having a heart attack). You often can't walk away (your employer chose your insurance plan; you go where it's accepted). You don't bear the full cost yourself (your insurance company pays most of it — which changes your behavior). And the person deciding what you consume (the doctor) is also the person who profits from that consumption (the more tests and treatments ordered, the more the doctor or hospital earns).

Healthcare is the market failure most Americans experience personally, and it is the most consequential market failure in terms of dollars. The U.S. spends about $4.5 trillion per year on healthcare — roughly 17% of GDP, or about $13,500 per person per year. That is nearly double what most peer countries spend, per capita. And by most health outcome measures (life expectancy, infant mortality, preventable deaths, chronic disease management), the U.S. performs worse than those peer countries, not better.

How is this possible? How can the world's richest country spend the most and get less? The answer, in economic terms, comes down to three interrelated market failures: information asymmetry, moral hazard, and adverse selection. This chapter walks through each, then compares four national healthcare systems, then addresses the most common U.S. policy debates.

14.1 Why healthcare is different: three market failures

Market failure 1 — Information asymmetry

Information asymmetry: one party to a transaction knows more than the other about the quality, cost, or necessity of the good being exchanged.

In most markets, the buyer knows at least roughly what they're getting. You can taste the pizza. You can test-drive the car. You can read reviews of the laptop. The seller also knows what they're selling. Information is not perfect but it's adequate.

In healthcare, the information asymmetry is extreme and structural:

• The patient doesn't know what they need. When you have chest pain, you don't know whether it's a heart attack, heartburn, a pulled muscle, or anxiety. The doctor does (or will, after tests). The doctor is simultaneously the person diagnosing your problem and the person selling you the solution. This is a principal-agent problem: the agent (doctor) makes decisions on behalf of the principal (patient), and the agent's incentives may not align perfectly with the principal's interests.

• The patient can't evaluate quality. You can judge whether a pizza is good. You usually cannot judge whether a surgery was performed well or whether a drug was prescribed appropriately. Medical quality is largely invisible to the consumer, and the metrics that do exist (mortality rates, infection rates, readmission rates) are available but rarely consulted by patients making decisions.

• Prices are opaque. Most patients have no idea what a medical procedure costs until after it happens. Prices vary wildly across providers (the same MRI can cost $400 at one facility and $2,500 at another in the same city). The price the patient pays depends on their insurance, their deductible, their network status, and a dozen other factors. Transparent pricing — the foundation of a functioning market — is largely absent.

The consequence of information asymmetry is that the standard supply-and-demand model, which assumes buyers know what they want and can evaluate what they're getting, breaks down. Patients can't shop effectively. They can't compare. They can't negotiate. They rely on their doctor's judgment, and the doctor may have incentives (fee-for-service payment, hospital pressure, liability concerns) that don't perfectly align with the patient's interest.

Market failure 2 — Moral hazard

Moral hazard: when having insurance changes the behavior of the insured person, typically by encouraging more consumption of the insured service.

When you have health insurance, you don't pay the full cost of your healthcare. Your insurance company pays most of it. A doctor's visit that costs $200 might cost you $20 (your copay). An MRI that costs $1,500 might cost you $150 (your coinsurance).

This is great for access — it means you're more likely to seek care when you need it. But it also means you're more likely to seek care when you don't need it, because the marginal cost to you is very low. You might go to the ER for a bad cold (cost to you: $50 copay; cost to the system: $1,500). You might agree to an expensive test your doctor recommends even though a wait-and-see approach would be clinically appropriate (cost to you: $100; cost to the system: $3,000).

Moral hazard in healthcare is well-documented. The RAND Health Insurance Experiment (1971–1982), one of the largest and most rigorous social experiments ever conducted, randomly assigned families to insurance plans with different levels of cost-sharing. The finding: people with lower cost-sharing (more generous insurance) used significantly more healthcare services. Some of the additional use was beneficial (preventive care, chronic disease management). Some of it was not (unnecessary tests, ER visits for minor complaints).

The design problem: the insurance system has to balance two goals that pull in opposite directions. Low cost-sharing (generous insurance) improves access but encourages overuse. High cost-sharing (high deductibles, high copays) reduces overuse but creates barriers to access, especially for low-income patients who may forgo necessary care because they can't afford the out-of-pocket cost.

Every healthcare system in the world struggles with this tradeoff. None has solved it completely.

Market failure 3 — Adverse selection

Adverse selection: when the people most likely to need insurance are the ones most likely to buy it, which can make insurance markets unstable.

Insurance works by pooling risk: healthy people and sick people pay premiums into a common pool, and the pool pays for the care of those who get sick. For the pool to be financially stable, it needs a mix of healthy and sick people — the premiums of the healthy subsidize the care of the sick.

The problem: if insurance is optional and priced at the average cost, healthy people may decide the premium isn't worth it ("I'm 25 and healthy — why pay $400/month for insurance I probably won't use?"). They drop out. The remaining pool is sicker on average, so the average cost rises. The premium goes up. More healthy people drop out. The pool gets sicker. The premium goes up further. This is the adverse selection spiral — sometimes called the death spiral — and it can cause an insurance market to collapse entirely.

The ACA (Affordable Care Act) addressed this with the individual mandate: a tax penalty for people who didn't buy insurance. The mandate was designed to keep healthy people in the pool, preventing the death spiral. The mandate was effectively eliminated in 2017 (the penalty was reduced to $0). Whether the ACA markets have remained stable without the mandate is debated; they have been more stable than many predicted, partly because the ACA's premium subsidies are generous enough to keep enrollment attractive even without the penalty.

The interaction of the three

The three failures reinforce each other. Information asymmetry means patients can't evaluate whether they're overusing (moral hazard) or whether their insurance premium is fair (adverse selection). Moral hazard drives up costs, which drives up premiums, which makes adverse selection worse. Adverse selection thins the risk pool, which makes insurance more expensive, which makes the information asymmetry problem worse (patients can't afford to shop around when their only affordable option is a narrow-network plan).

The interaction is what makes healthcare so hard to fix. Solving one problem often worsens another. Reducing moral hazard (high deductibles) worsens access for the poor. Reducing adverse selection (mandates) reduces individual freedom. Reducing information asymmetry (transparent pricing) helps but doesn't fix the fundamental problem that patients can't diagnose themselves.

14.2 The U.S. system: how the world's richest country spends the most and gets less

The U.S. healthcare system is a hybrid — neither fully public nor fully private. About 35% of healthcare spending comes from the federal government (mostly Medicare and Medicaid). About 10% comes from state and local governments. About 30% comes from private insurance (mostly employer-sponsored). About 10% comes from out-of-pocket payments. The rest is a mix of other sources.

The system costs about $4.5 trillion per year (2024 estimate) — roughly $13,500 per person, or about 17% of GDP. By comparison: - Germany: ~$7,400 per person (12.7% of GDP) - France: ~$5,600 per person (12.1% of GDP) - UK: ~$5,100 per person (11.3% of GDP) - Canada: ~$5,700 per person (12.2% of GDP) - Japan: ~$4,700 per person (11.0% of GDP)

The U.S. spends nearly double the rich-country average per person. And the outcomes? - Life expectancy: U.S. ~77 years (lowest among rich countries; peer average ~82) - Infant mortality: U.S. ~5.4 per 1,000 live births (peer average ~3.5) - Preventable deaths: the U.S. has the highest rate of preventable deaths among rich countries - Chronic disease management: worse than most peers on diabetes, heart disease, and respiratory disease outcomes

The pattern is clear: more money, worse outcomes. How?

Three reasons the U.S. pays more

1. Higher prices, not more services. Americans do not use more healthcare services than people in other rich countries. They use about the same number of doctor visits, hospital admissions, and procedures. What's different is the price of each service. A hospital day in the U.S. costs roughly $5,000; in France it costs about $1,000. An MRI in the U.S. costs $1,100 on average; in the UK it costs about $300. Drug prices are much higher (because the U.S. does not negotiate drug prices at the national level the way most other countries do). The famous line from health economist Gerard Anderson: "It's the prices, stupid."

2. Administrative complexity. The U.S. healthcare system has hundreds of insurance companies, each with different rules, different networks, different billing systems, and different prior-authorization requirements. Hospitals and doctors' offices spend enormous amounts on billing and administration — estimated at 15–30% of total healthcare spending, versus 5–10% in single-payer systems. The administrative overhead is pure waste from a health-delivery standpoint.

3. Fragmented coverage. About 26 million Americans (8% of the population, as of 2023) have no health insurance at all. Many more are underinsured — they have insurance but with deductibles and copays so high that they delay or forgo necessary care. Uninsured and underinsured patients tend to use emergency departments for routine care (the most expensive delivery setting), and they tend to present with advanced disease (because they delayed seeking care), which is more expensive to treat.

Three reasons it's hard to change

1. Concentrated interests. The current system generates enormous revenue for hospitals, drug companies, insurance companies, medical device manufacturers, and specialist physicians. Each of these groups has powerful lobbying operations and is strongly motivated to resist changes that would reduce their revenue.

2. Employer-sponsored insurance creates lock-in. About half of all Americans get their health insurance through their employer. Employer-sponsored insurance is tax-advantaged (premiums are excluded from taxable income), which makes it artificially attractive. But it also ties coverage to employment, which means losing your job means losing your insurance — a unique-to-America arrangement that most other countries find bizarre.

3. Ideological polarization. Healthcare has become one of the most polarized policy issues in American politics. "Medicare for All" (single-payer) is supported by the progressive wing of the Democratic Party and opposed by virtually all Republicans and many moderate Democrats. The ACA remains politically contested a decade after passage. Even modest reforms (allowing Medicare to negotiate drug prices, expanding Medicaid in holdout states) face fierce opposition.

14.3 Four healthcare systems compared

No country has a perfect healthcare system. Every system involves tradeoffs among cost, access, quality, and choice. Here are four models, each with distinct strengths and weaknesses.

Model 1 — US mixed system

How it works: multiple payers (private insurance, Medicare for 65+, Medicaid for low-income, ACA marketplace, VA for veterans, self-pay). No single authority controls prices or coverage.

Strengths: high-quality specialist care (the U.S. leads in some advanced treatments); innovation incentives (high prices reward drug and device development); choice for those with good insurance.

Weaknesses: highest cost in the world, worst outcomes among rich countries, 26 million uninsured, enormous administrative waste, price opacity, fragmented coverage.

Model 2 — UK National Health Service (single-payer, government-run)

How it works: the government owns the hospitals, employs the doctors, and provides care directly. Funded by taxes. Free at the point of use.

Strengths: universal coverage, low administrative costs, low per-capita spending (~$5,100), no bills or billing disputes, good primary care.

Weaknesses: long wait times for specialist and elective care, underfunding (the NHS has been chronically under-resourced since the 2010s), limited patient choice, some innovation lag.

Model 3 — Canada (single-payer, privately delivered)

How it works: the government pays for care (single-payer), but hospitals and doctors are mostly private. Provincial governments negotiate prices with providers.

Strengths: universal coverage, simpler administration than the U.S., no bills, good outcomes on most metrics.

Weaknesses: long wait times (especially for specialist care and elective surgery), limited coverage of dental, vision, and prescription drugs (these are often paid out-of-pocket or through supplemental private insurance).

Model 4 — Singapore (mixed with mandatory savings)

How it works: a combination of mandatory health savings accounts (MediSave), catastrophic insurance (MediShield), and a government safety net (MediFund). Patients pay substantial out-of-pocket costs, which reduces moral hazard. The government controls prices aggressively.

Strengths: low per-capita spending (~$2,800), good outcomes, strong cost control, patient skin-in-the-game reduces overuse.

Weaknesses: substantial out-of-pocket costs can burden low-income patients; the system works partly because Singapore is small, wealthy, and young (the demographic profile may not be replicable).

The comparative lesson

No system is the "right" one. Each makes different tradeoffs: - The U.S. prioritizes choice and innovation at the cost of equity and efficiency - The UK prioritizes equity and cost control at the cost of choice and timeliness - Canada prioritizes equity and simplicity at the cost of timeliness - Singapore prioritizes cost control and personal responsibility at the cost of equity for the poorest

The right system for a particular country depends on its values, its demographics, its institutional capacity, and its political constraints. Economics can compare the tradeoffs. It cannot choose among them.

14.4 The COVID lens on healthcare

The COVID pandemic exposed both the strengths and the weaknesses of the U.S. healthcare system in a single event:

Strengths exposed: rapid vaccine development (Operation Warp Speed produced effective vaccines in under a year — an unprecedented achievement), treatment innovation (monoclonal antibodies, antiviral pills, improved ventilation protocols), and world-class intensive care capacity.

Weaknesses exposed: uneven access (uninsured and underinsured patients delayed seeking care and had worse outcomes), the "essential worker" gap (the workers society depended on most — nurses, aides, cleaners — were among the lowest-paid and most exposed), the fragmentation problem (no single authority coordinated the public health response nationally), and the cost problem (COVID hospitalizations cost an average of $40,000–$80,000 per admission, and many patients faced ruinous bills even with insurance).

The pandemic also demonstrated the public-good dimension of healthcare. Vaccination is a positive externality (Chapter 11): your vaccination protects me. Healthcare access during a pandemic is (partially) a public good: widespread access to testing, treatment, and vaccination reduces transmission for everyone. The pandemic strengthened the case for universal healthcare access as a public health measure, not just an equity measure.

14.5 What this chapter could not settle

The chapter gave you the three market failures (information asymmetry, moral hazard, adverse selection), the comparative framework (four systems, four sets of tradeoffs), and the data on U.S. spending and outcomes. It did not — and cannot — tell you which system the U.S. should adopt.

The honest framing: the U.S. healthcare system is uniquely expensive and uniquely poor-performing among rich countries, and the reasons are structural (prices, administrative complexity, fragmented coverage), not mysterious. Fixing the system requires some combination of cost control, coverage expansion, and administrative simplification. The specific combination you favor depends on your values — how much you weight choice, equity, innovation, cost control, and personal responsibility.

The political constraints are real. The current system generates trillions of dollars in revenue for powerful interests, each of which resists changes that would reduce its share. Reform is not an intellectual problem; it is a political problem. The economic analysis identifies the options and the tradeoffs. The politics determines which options are feasible.

Key terms recap: information asymmetry — one party knows more than the other moral hazard — insurance changes behavior toward overuse adverse selection — sicker people are more likely to buy insurance, destabilizing pools principal-agent problem — the agent (doctor) decides for the principal (patient) and may have misaligned incentives third-party payer — someone other than the patient pays most of the bill single-payer — one payer (usually government) funds all care ACA — Affordable Care Act (2010); expanded coverage, created marketplaces, individual mandate death spiral — adverse selection loop where premiums rise and healthy people drop out

Themes touched: Markets power+imperfect (healthcare is the most dramatic market failure most readers experience), Tradeoffs (every system makes different ones), Disagreement (about which system is best), Behavioral (moral hazard is partly a behavioral phenomenon), Affects daily life (healthcare costs, access, bills, insurance).